Drug Class Description
Blood coagulation factor VIII (human), glycoform a.
Generic Name
Factor VIII [octocog alfa]
Drug Description
Blood coagulation factor VIII (human), glycoform a produced from genetically engineered baby hamster kidney cells containing a cloned human Factor VIII gene. Powder in vials plus WFI and administration set.
Presentation
Powder for injection, octocog alfa with nominal haemophilic factor activities of 250 i.u. , 500 i.u. , 1,000 i.u.
Indications
Congenital Factor VIII deficiency (haemophilia A) for the treatment and prophylaxis of bleeding in untreated and previously treated patients without inhibitors. Treatment can be continued in patients who develop Factor VIII inhibitors and who continue to respond to Kogenate. Kogenate does not contain von Willebrand Factor and hence is not indicated in von Willebrand's disease.
Adult Dosage
1 - 2 mL/minute by slow 1 - 2 mL/minute by slow intravenous infusion according to body weight, severity of haemorrhage and presence of inhibitors.
Child Dosage
1 - 2 mL/minute by slow intravenous infusion according to body weight, severity of haemorrhage and presence of inhibitors. Refer to Summary of Product Characteristics.
Contra Indications
Known allergic reactions to constituents of preparation. Known hypersensitivity to mouse or hamster protein.
Special Precautions
Pregnancy, lactation. Monitor for Factor VIII inhibitors and activity regularly. If hypersensitivity occurs, discontinue treatment.
Interactions
None known.
Adverse Reactions
Local reactions at injection site (eg, burning, transient erythema, rash), hypersensitivity (chest tightness, dizziness, mild hypotension, nausea). Anaphylactic shock. Development of inhibitors.
Manufacturer
Bayer
Drug Availability
(POM)
Updated
15 May 2009 
